Ziprasidone induces cytotoxicity and genotoxicity in human peripheral lymphocytes
. (Source: Drug and Chemical Toxicology)
Source: Drug and Chemical Toxicology - November 29, 2016 Category: Toxicology Authors: Haluk Kefelio ğlu Z ülal Atlı Şekeroğlu Gamze Co şguner Seval Konta ş Yedier Vedat Şekeroğlu Source Type: research

Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics
ConclusionThe occurrence of EPS in SGA users is a common finding, with no difference of antipsychotics studied in relation to the risk of extrapyramidal manifestations. The adjunctive use of carbamazepine may predispose the user of SGA to the occurrence of EPS. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - November 26, 2016 Category: Drugs & Pharmacology Source Type: research

Haloperidol plus promethazine for psychosis-induced aggression.
CONCLUSIONS: Haloperidol plus promethazine is effective and safe, and its use is based on good evidence. Benzodiazepines work, with midazolam being particularly swift, but both midazolam and lorazepam cause respiratory depression. Olanzapine intramuscular and ziprasidone intramuscular do seem to be viable options and their action is swift, but resumption of aggression with subsequent need to re-inject was more likely than with haloperidol plus promethazine. Haloperidol used on its own without something to offset its frequent and serious adverse effects does seem difficult to justify. PMID: 27885664 [PubMed - as suppli...
Source: Cochrane Database of Systematic Reviews - November 25, 2016 Category: Journals (General) Authors: Huf G, Alexander J, Gandhi P, Allen MH Tags: Cochrane Database Syst Rev Source Type: research

Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.
CONCLUSIONS: Adjunctive ziprasidone, added to escitalopram, led to a greater weight gain and greater but modest akathisia compared to placebo. The effect of ziprasidone on QTc showed a trend toward significance, and therefore caution should be used in the administration of ziprasidone. While ziprasidone augmentation in patients with MDD appears safe, precautions should be taken in practice, specifically regular monitoring of electrocardiogram, weight, extrapyramidal symptoms, and involuntary movements. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00633399​​. PMID: 27835715 [PubMed - as supplied by publ...
Source: Journal of Clinical Psychiatry - November 13, 2016 Category: Psychiatry Tags: J Clin Psychiatry Source Type: research

Ziprasidone Augmentation for MDD Appears Safe, But Precautions Advised
Although the atypical antipsychotic ziprasidone has shown promise as an add-on therapy for patients with major depressive disorder (MDD), little is known of possible side effects from this intervention. Astudy in theJournal of Clinical Psychiatry now suggests that patients with MDD who take ziprasidone in combination with escitalopram may be at greater risk of weight gain, akathisia, and an increase in the QT interval compared with those taking escitalopram alone. The findings were based on a randomized, double-blind, placebo-controlled trial of 139 adults with MDD who were assigned to take ziprasidone (mean dose...
Source: Psychiatr News - November 10, 2016 Category: Psychiatry Tags: AJP antipsychotic-induced weight gain David Mischoulon depression escitalopram Journal of Clinical Psychiatry MDD QT prolongation ziprasidone Source Type: research

An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders
Conclusions We conclude that combining ZIP and OLZ at the outset of treatment is superior to switching from OLZ to ZIP in terms of improving psychotic symptoms and limiting movement side effects without increasing the risk of metabolic syndrome. (Source: Journal of Psychiatric Research)
Source: Journal of Psychiatric Research - November 10, 2016 Category: Psychiatry Source Type: research

A new simple and rapid validated RP-HPLC method for determination of ziprasidone in ziprasidone capsules
Publication date: September 2016 Source:Journal of Saudi Chemical Society, Volume 20, Supplement 1 Author(s): Ruchi Bansal, Karthikeyan Chandrabose, N.S. Hari Narayana Moorthy, Dhirendra Pratap Singh, Digvijay Singh, Piyush Trivedi In this work, a new isocratic reverse phase chromatographic method was developed using HPLC for ziprasidone hydrochloride monohydrate (ZHM). The newly developed method is applicable for assay determination of the ZHM in capsule dosage form. The chromatographic separation of ZHM was achieved on a Zorbax SB C-8 (50×4.6)mm, 3.5μm column within a short runtime of 2min. The method was valid...
Source: Journal of Saudi Chemical Society - October 31, 2016 Category: Chemistry Source Type: research

Ziprasidone augmentation for anxious depression
Previously, we found an anxiolytic effect of ziprasidone augmentation to escitalopram (compared with placebo augmentation) in patients with depression in an 8-week, randomized, double-blind, parallel-group, placebo-controlled trial. Here, we carried out a post-hoc analysis, comparing changes in the Hamilton Depression and Anxiety Rating Scales between patients with anxious depression versus nonanxious depression, using a moderator analysis. Hamilton Depression Rating Scales total change scores from baseline and endpoint were not significantly different (interaction term P=0.91) in patients with anxious depression on zipras...
Source: International Clinical Psychopharmacology - September 29, 2016 Category: Psychiatry Tags: Original Articles Source Type: research

Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study
AbstractRationalePatients with schizophrenia spectrum disorders have increased morbidity and mortality, largely due to cardiovascular disease, which is associated with antipsychotic treatment.ObjectivesBecause of the link between cardiometabolic risk, non-alcoholic fatty liver disease (NAFLD), and antipsychotics, we aimed to investigate the development of NAFLD during the first 3  years of antipsychotic treatment in first episode non-affective psychosis patients.ResultsA sample of 191 subjects was included in final analyses, randomly assigned to aripiprazole (N = 83), risperidone (N = 12), que...
Source: Psychopharmacology - September 12, 2016 Category: Psychiatry Source Type: research

Two Sudden and Unexpected Deaths of Patients with Schizophrenia Associated with Intramuscular Injections of Antipsychotics and Practice Guidelines to Limit the Use of High Doses of Intramuscular Antipsychotics.
Authors: Wahidi N, Johnson KM, Brenzel A, de Leon J Abstract Intravenous haloperidol has been associated with torsades de pointes (TdP). These two sudden deaths were probable adverse drug reactions (ADRs) following intramuscular (IM) antipsychotics. The autopsies described lack of heart pathology and were highly compatible with the possibility of TdP in the absence of risk factors other than the accumulation of antipsychotics with a high serum peak after the last injection, leading to death within hours. The first case was a 27-year-old African-American male with schizophrenia but no medical issues. His death was p...
Source: Case Reports in Psychiatry - September 8, 2016 Category: Psychiatry Tags: Case Rep Psychiatry Source Type: research

Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach
Publication date: Available online 25 August 2016 Source:The Lancet Psychiatry Author(s): Nikolaos Koutsouleris, René S Kahn, Adam M Chekroud, Stefan Leucht, Peter Falkai, Thomas Wobrock, Eske M Derks, Wolfgang W Fleischhacker, Alkomiet Hasan Background At present, no tools exist to estimate objectively the risk of poor treatment outcomes in patients with first-episode psychosis. Such tools could improve treatment by informing clinical decision-making before the commencement of treatment. We tested whether such a tool could be successfully built and validated using routinely available, patient-reportable informatio...
Source: The Lancet Psychiatry - August 26, 2016 Category: Psychiatry Source Type: research

Metformin May Curb Weight Gain in Youth Taking Antipsychotics for Autism
Although atypical antipsychotic medications can help to reduce irritability and agitation in youth with autism spectrum disorder (ASD), these medications are known to cause weight gain and may increase risk of diabetes. Asmall trial published online yesterday inJAMA Psychiatry suggests that metformin, a drug used for treatment of type 2 diabetes, may decrease weight gain in children with ASD.Evdokia Anagnostou, M.D., a senior clinician scientist at the Bloorview Research Institute in Toronto, and colleagues randomly assigned 61 young people (aged 6 to 17) with ASD to receive metformin or placebo for 16 weeks. (All of ...
Source: Psychiatr News - August 25, 2016 Category: Psychiatry Tags: atypical antipsychotics autism autism spectrum disorder Bloorview Christopher McDougle Evdokia Anagnostou Metformin psychiatry Source Type: research

The quality of lactation studies including antipsychotics
ConclusionExcept for two studies, most studies about the safety of antipsychotic use during lactation did not meet the criteria of the draft FDA and ILCA guidelines. Further research is mandatory to assess the safety of using antipsychotics while breastfeeding. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - August 24, 2016 Category: Drugs & Pharmacology Source Type: research

Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review
AbstractImplementing the most suitable treatment strategies and making appropriate clinical decisions about individuals with a first episode of psychosis (FEP) is a complex and crucial task, with relevant impact in illness outcome. Treatment approaches in the early stages should go beyond choosing the right antipsychotic drug and should also address tractable factors influencing the risk of relapse. Effectiveness and likely metabolic and endocrine disturbances differ among second-generation antipsychotics (SGAs) and should guide the choice of the first-line treatment. Clinicians should be aware of the high risk of cardiova...
Source: Neurology and Therapy - August 23, 2016 Category: Neurology Source Type: research

Antipsychotic Use Early in Pregnancy Does Not Appear to Increase Risk of Birth Defects
With the possible exception of risperidone, taking antipsychotics early in pregnancy does not appear to significantly increase the risk of newborns having birth defects, a study published yesterday inJAMA Psychiatryreports. According to the study authors, more research is needed to understand the small increase in risk for malformations associated with risperidone.To examine the risk for congenital defects associated with first-trimester exposure to different antipsychotics, Krista Huybrechts, M.S., Ph.D., of Brigham and Women ’s Hospital and Harvard Medical School, Boston, and colleagues analyzed a nationwide s...
Source: Psychiatr News - August 18, 2016 Category: Psychiatry Tags: antipsychotics aripiprazole cardiac defects JAMA Psychiatry Katherine Wisner Krista Huybrechts olanzapine pregnancy quetiapine risperidone ziprasidone Source Type: research

Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits?
This article briefly reviews the role of adjunctive therapy with SGAs in contemporary algorithms for TRD, considering both the evidence of benefit and the adverse effects. PMID: 27514300 [PubMed - in process] (Source: The Medical Clinics of North America)
Source: The Medical Clinics of North America - August 17, 2016 Category: Journals (General) Authors: Thase ME Tags: Psychiatr Clin North Am Source Type: research

The effect of second-generation antipsychotic drugs on sleep parameters in patients with unipolar or bipolar disorder
• Sleep disturbance in patients with unipolar disorder may take either the form of insomnia or hypersomnia, with the latter occurring less frequently.• Patients with bipolar disorder may show decreased need for sleep without dissatisfaction with sleep quality.• Severe insomnia in unipolar and bipolar disorder patients may be a risk factor for the development of a major depressive episode and suicidal behavior.• Second-generation antipsychotic drugs such as olanzapine, quetiapine and ziprasidone improve sleep architecture, and could improve sleep disturbance in unipolar and bipolar diso rder patients. (S...
Source: Sleep Medicine - August 11, 2016 Category: Sleep Medicine Authors: Jaime M. Monti Tags: Review Article Source Type: research

Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases
Conclusion: Despite the significant burden mental disorders impose on society, investment and pharmaceutical innovation in this disease area remains comparatively low. Policymakers should consider new strategies to stimulate public and private investment in the research and development of novel and effective therapies to treat schizophrenia and other mental disorders. Introduction Over the last two decades, there have been remarkable breakthroughs in healthcare. These breakthroughs include the development of novel pharmaceutical treatments that have significantly improved outcomes for patients suffering from various medica...
Source: Innovations in Clinical Neuroscience - August 1, 2016 Category: Neuroscience Authors: ICN Online Editor Tags: Bipolar Disorder Current Issue Drug Development Mental Disorders Mood Disorders Original Research Psychiatry Psychopharmacology disease burden expenditures major depressive disorder pharmaceutical innovation research and developmen Source Type: research

Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures.
Authors: Donohue JM, Normand SL, Horvitz-Lennon M, Men A, Berndt ER, Huskamp HA Abstract BACKGROUND: Regional variation in US Medicare prescription drug spending is driven by higher prescribing of costly brand-name drugs in some regions. This variation likely arises from differences in the speed of diffusion of newly-approved medications. Second-generation antipsychotics were widely adopted for treatment of severe mental illness and for several off-label uses. Rapid diffusion of new psychiatric drugs likely increases drug spending but its relationship to non-drug spending is unclear. The impact of antipsychotic dif...
Source: Journal of Mental Health Policy and Economics - July 29, 2016 Category: Psychiatry Tags: J Ment Health Policy Econ Source Type: research

Antioxidant properties of atypical antipsychotic drugs used in the treatment of schizophrenia
The aim of this study was to compare the antioxidant activities of six atypical antipsychotic drugs: clozapine (CLZ), quetiapine, olanzapine (OLA), risperidone, ziprasidone, aripiprazole (ARI), as well as a typical antipsychotic drug, haloperidol. Several tests of antioxidant activity were used: protection of thiol groups against oxidation by peroxynitrite (PN) and 3-morpholinosydnonimine (SIN-1, generator of PN), oxidation of dihydrorhodamine 123 by PN, SIN-1 and hypochlorite (NaOCl), bleaching of fluorescein fluorescence by PN, 2,2′-azobis(2-amidinopropane) dihydrochloride (AAPH, generator of peroxyl radicals) and ...
Source: Schizophrenia Research - July 20, 2016 Category: Psychiatry Authors: Izabela Sadowska-Bartosz, Sabina Galiniak, Grzegorz Bartosz, Mariusz Zuberek, Agnieszka Grzelak, Anna Dietrich-Muszalska Source Type: research

Antioxidant properties of atypical antipsychotic drugs used in the treatment of schizophrenia
The aim of this study was to compare the antioxidant activities of six atypical antipsychotic drugs: clozapine (CLZ), quetiapine, olanzapine (OLA), risperidone, ziprasidone, aripiprazole (ARI), as well as a typical antipsychotic drug, haloperidol. Several tests of antioxidant activity were used: protection of thiol groups against oxidation by peroxynitrite (PN) and 3-morpholinosydnonimine (SIN-1, generator of PN), oxidation of dihydrorhodamine 123 by PN, SIN-1 and hypochlorite (NaOCl), bleaching of fluorescein fluorescence by PN, 2,2 ′-azobis(2-amidinopropane) dihydrochloride (AAPH, generator of peroxyl radicals) and...
Source: Schizophrenia Research - July 20, 2016 Category: Psychiatry Authors: Izabela Sadowska-Bartosz, Sabina Galiniak, Grzegorz Bartosz, Mariusz Zuberek, Agnieszka Grzelak, Anna Dietrich-Muszalska Source Type: research

Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management
Abstract Somnolence is a common side effect of antipsychotics. To assess the incidence of this side effect, we performed a MEDLINE search for randomized, double-blinded, placebo- or active-controlled studies of adult patients treated with antipsychotics for schizophrenia, mania, bipolar depression, or bipolar disorder. We extracted rates of somnolence from original publications and pooled them based on the dose of each antipsychotic in the same psychiatric condition, then estimated the absolute risk increase (ARI) and the number needed to harm (NNH) of an antipsychotic relative to placebo or an active comparator i...
Source: CNS Drugs - July 2, 2016 Category: Neurology Source Type: research

A Case of Sleepwalking With Sleep-Related Eating Associated With Ziprasidone Therapy in a Patient With Schizoaffective Disorder
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - June 30, 2016 Category: Psychiatry Tags: Letters to the Editors - Case Reports Source Type: research

An update of safety of clinically used atypical antipsychotics.
Authors: Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo A, Martinotti G, Mazza M, Perna G, Carano A, de Bartolomeis A, Di Giannantonio M, De Berardis D Abstract INTRODUCTION: The atypical antipsychotic (APs) drugs are a class of agents that have become the most widely used agents to treat a variety of psychoses because of their superiority with regard to safety and tolerability profile, particularly regarding to their lower/absent propensity to induce extrapyramidal symptoms (EPS), compared to conventional/'typical' APs. AREAS COVERED: We ...
Source: Expert Opinion on Drug Safety - June 29, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

A Bibliometric Study on Second-generation Antipsychotic Drugs in the Asia –Pacific Region
Publication date: August 2014 Source:Journal of Experimental & Clinical Medicine, Volume 6, Issue 4 Author(s): Francisco López-Muñoz, Winston W. Shen, Naotaka Shinfuku, Chi-Un Pae, David J. Castle, Albert K. Chung, Kang Sim, Cecilio Álamo In this review, we analyzed the status and changes in the research on second-generation (atypical) antipsychotic drugs in the Asia–Pacific region (i.e., Japan, South Korea, Taiwan, Hong Kong, Singapore, and Australia). We also performed a bibliometric study of the literature in this region on atypical antipsychotic drugs (e.g., clozapine, rispe...
Source: Journal of Experimental and Clinical Medicine - June 18, 2016 Category: Journals (General) Source Type: research

Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants
This article briefly reviews the role of adjunctive therapy with SGAs in contemporary algorithms for TRD, considering both the evidence of benefit and the adverse effects. (Source: The Psychiatric Clinics of North America)
Source: The Psychiatric Clinics of North America - June 17, 2016 Category: Psychiatry Authors: Michael E. Thase Source Type: research

Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants
This article briefly reviews the role of adjunctive therapy with SGAs in contemporary algorithms for TRD, considering both the evidence of benefit and the adverse effects. (Source: Psychiatric Clinics of North America)
Source: Psychiatric Clinics of North America - June 17, 2016 Category: Psychiatry Source Type: research

Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants
This article briefly reviews the role of adjunctive therapy with SGAs in contemporary algorithms for TRD, considering both the evidence of benefit and the adverse effects. (Source: The Psychiatric Clinics of North America)
Source: The Psychiatric Clinics of North America - June 17, 2016 Category: Psychiatry Authors: Michael E. Thase Source Type: research

Antipsychotic medications for the treatment of delirium: a systematic review and meta-analysis of randomised controlled trials
Conclusions Our results suggested that SGAs have a benefit for the treatment of delirium with regard to efficacy and safety compared with haloperidol. However, further study using larger samples is required. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - June 14, 2016 Category: Neurosurgery Authors: Kishi, T., Hirota, T., Matsunaga, S., Iwata, N. Tags: Delirium, Drugs: psychiatry, Memory disorders (psychiatry), Psychotic disorders (incl schizophrenia) Neuropsychiatry Source Type: research

Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models.
This study demonstrated that both clozapine and olanzapine have antioxidant effects, in vitro, by scavenging superoxide anion on the respiratory burst, donating electron in the ABTS(+) assay and stabilizing the radical DPPH. Ziprasidone significantly scavenged ABTS(+) and stabilized the radical DPPH whereas risperidone significantly reduced the respiratory burst. Haloperidol and quetiapine lacked antioxidant effects. The chemical structure-related antioxidant capacity suggests a possible neuroprotective mechanism of these drugs on the top of their antipsychotic mechanism of action. PMID: 27261620 [PubMed - as supplied...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 5, 2016 Category: Drugs & Pharmacology Authors: Brinholi FF, Farias CC, Bonifácio KL, Higachi L, Casagrande R, Moreira EG, Barbosa DS Tags: Biomed Pharmacother Source Type: research

Effects of antipsychotics on insight in schizophrenia: results from independent samples of first-episode and acutely relapsed patients
We aimed to investigate whether antipsychotics differentially impact insight and whether these effects appear because of improvement in psychopathological manifestation in 132 first-episode schizophrenia patients and 201 acutely relapsed schizophrenic patients, who were followed up for 12 weeks. Olanzapine and risperidone were administered to first-episode schizophrenia patients, whereas acutely relapsed schizophrenic patients were treated with olanzapine, perazine and ziprasidone. The Positive And Negative Syndrome Scale (PANSS) was used to assess psychopathology. Insight was assessed using the G12 item of PANSS. Unadjust...
Source: International Clinical Psychopharmacology - June 4, 2016 Category: Psychiatry Tags: Original Articles Source Type: research

Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record.
CONCLUSIONS: Mandatory intake testing increases the number of patients evaluated for metabolic syndrome. Electronic alerts increase the inclusion of metabolic syndrome among discharge diagnoses but rarely affect prescribing practices. PMID: 27247842 [PubMed] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - June 3, 2016 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research

The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia
Insomnia is a common feature in schizophrenia, and is characterized by an increase of sleep latency (SL), as well as reductions in total sleep time (TST) and sleep efficiency (SE). Regarding sleep architecture, non-rapid-eye-movement (NREM) sleep, slow wave sleep (SWS) and rapid-eye-movement (REM) sleep latency are decreased, whereas REM sleep tends to remain unchanged. According to polysomnographic studies, clozapine, olanzapine, quetiapine and ziprasidone administration increased TST and/or SE in healthy subjects. (Source: Sleep Medicine Reviews)
Source: Sleep Medicine Reviews - May 15, 2016 Category: Sleep Medicine Authors: Jaime M. Monti, Pablo Torterolo, Seithikurippu R. Pandi Perumal Source Type: research

Ziprasidone
(Source: Reactions Weekly)
Source: Reactions Weekly - May 1, 2016 Category: Drugs & Pharmacology Source Type: research

Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models
This study demonstrated that both clozapine and olanzapine have antioxidant effects, in vitro, by scavenging superoxide anion on the respiratory burst, donating electron in the ABTS+ assay and stabilizing the radical DPPH. Ziprasidone significantly scavenged ABTS+ and stabilized the radical DPPH whereas risperidone significantly reduced the respiratory burst. Haloperidol and quetiapine lacked antioxidant effects. The chemical structure-related antioxidant capacity suggests a possible neuroprotective mechanism of these drugs on the top of their antipsychotic mechanism of action. (Source: Biomedicine and Pharmacotherapy)
Source: Biomedicine and Pharmacotherapy - April 28, 2016 Category: Drugs & Pharmacology Source Type: research

Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety
Conclusions: The current data suggest that SGAs seem to be relatively safe in the exposed breastfed infants for short-term usage. However, additional studies, in particular for antipsychotics other than olanzapine, examining short-term and especially long-term effects of SGAs on the breastfed infants are required. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - April 20, 2016 Category: Psychiatry Tags: Review Article Source Type: research

Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade
We report the use of the cascade in profiling two small libraries containing clinically tested compounds and identify Clemastine, Azelastine, Ifenprodil, Ziprasidone and Clofibrate as molecules having appropriate profiles. Analysis of clinical derived pharmacokinetic and toxicity data indicates that none of these are appropriate for repurposing but they may represent suitable start points for further optimisation for the treatment of Chagas disease. (Source: PLoS Neglected Tropical Diseases)
Source: PLoS Neglected Tropical Diseases - April 15, 2016 Category: Tropical Medicine Authors: Manu De Rycker Source Type: research

Acute Pancreatitis Associated With Antipsychotic Medication: Evaluation of Clinical Features, Treatment, and Polypharmacy in a Series of Cases
Discussion: We identified 41 reports of antipsychotic-related acute pancreatitis, many associated with antipsychotic polypharmacy. Olanzapine, risperidone, quetiapine, aripiprazole, and ziprasidone are associated with acute pancreatitis and often in combination with mood stabilizers. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - March 4, 2016 Category: Psychiatry Tags: Brief Reports Source Type: research

Insight and recovery in schizophrenic patients.
Conclusions Only a small proportion of schizophrenic patients achieved recovery, therefore greater patient's insight could have prognostic validity in terms of treatment outcome. More sensitive instruments and a larger sample are necessary to confirm these results. PMID: 26902557 [PubMed - as supplied by publisher] (Source: International Journal of Psychiatry in Clinical Practice)
Source: International Journal of Psychiatry in Clinical Practice - February 24, 2016 Category: Psychiatry Tags: Int J Psychiatry Clin Pract Source Type: research

Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis
This study modelled the cost-effectiveness of 11 oral antipsychotics for relapse prevention among patients with remitted schizophrenia in Singapore. A network meta-analysis determined the relative efficacy and tolerability of 11 oral antipsychotics (amisulpride, aripiprazole, chlorpromazine, haloperidol, olanzapine, paliperidone, quetiapine, risperidone, sulpiride, trifluoperazine and ziprasidone). The clinical estimates were applied in a Markov model to estimate lifetime costs and quality-adjusted life-years gained. Quality-of-life data were obtained from published literature. Resource utilization and cost data were retri...
Source: International Clinical Psychopharmacology - February 3, 2016 Category: Psychiatry Tags: Original Articles Source Type: research

Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
Abstract Ziprasidone is a poorly water-soluble antipsychotic drug that demonstrates low fasted state oral bioavailability and a clinically significant two-fold increase in absorption when dosed postprandially. Owing to significant compliance challenges faced by schizophrenic patients, a novel oral formulation of ziprasidone that demonstrates improved fasted state absorption and a reduced food effect is of major interest, and is therefore the aim of this research. Three lipid-based drug delivery systems (LBDDS) were developed and investigated: (a) a self-nanoemulsifying drug delivery system (SNEDDS), (b) a solid SN...
Source: European Journal of Pharmaceutics and Biopharmaceutics - January 23, 2016 Category: Drugs & Pharmacology Authors: Dening TJ, Rao S, Thomas N, Prestidge CA Tags: Eur J Pharm Biopharm Source Type: research

A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia
Conclusions Many of the treatments are efficacious in controlling symptoms, and all showed a trend of superiority vs placebo for total, positive and negative PANSS scores, although only olanzapine and risperidone yielded statistically significant results vs placebo for both total and positive PANSS scores. Varying results for discontinuation and weight gain demonstrate a need to balance efficacy with side-effect profiles. (Source: CNS Drugs)
Source: CNS Drugs - January 22, 2016 Category: Neurology Source Type: research

Among the severely mentally ill, who responds to ziprasidone?
This study examines some differences in response to ziprasidone, which has been shown to be effective, with a better metabolic side effect profile, but was little used in New York State Hospitals. The aim was to study state hospital patients switched to ziprasidone. The results led to questions about different responses in different groups. Subjects from state hospitals who needed a change of antipsychotic participated in this openlabel 8 week trial of up to 240 mg ziprasidone. Analyses included comparisons of the very different results from two sites. Of the 36 study subjects, 12 terminated early. The 17 outpatients from ...
Source: Clinical Schizophrenia and Related Psychoses - January 19, 2016 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Quantification of selected antidepressants and antipsychotics in clinical samples using chromatographic methods combined with mass spectrometry: A review (2006-2015).
CONCLUSIONS: This review describes major advances and drawbacks in the field of chromatography coupled with single or tandem mass spectrometry (LC-MS, LC-MS/MS and GC/MS) of selected antidepressants (agomelatine, vilazodone) and antipsychotics (iloperidone, asenapine, amisulpride, aripiprazole, melperone, zotepine, ziprasidone). The high specificity in combination with high sensitivity makes these techniques an attractive complementary method to traditional procedures used in routine practice for TDM. PMID: 26757776 [PubMed - as supplied by publisher] (Source: Biomedical Papers of the Medical Faculty of the Univ Palack...
Source: Biomedical Papers of the Medical Faculty of the Univ Palacky Olomouc Czech Repub - January 16, 2016 Category: Biomedical Science Tags: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Source Type: research

Preparation and evaluation of ziprasidone–phospholipid complex from sustained‐release pellet formulation with enhanced bioavailability and no food effect
ConclusionsThe results indicated a sustained release with prolonged actions of schizophrenia and bipolar disorder treatment. (Source: Journal of Pharmacy and Pharmacology)
Source: Journal of Pharmacy and Pharmacology - January 8, 2016 Category: Drugs & Pharmacology Authors: Yanfei Miao, Guoguang Chen, Lili Ren, Pingkai Ouyang Tags: Research Paper Source Type: research

Effect of Ziprasidone Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week, Open-Label Uncontrolled Preliminary Study
Conclusions: The findings provide evidence that ziprasidone added to ongoing treatment appeared to be mildly effective to improve symptoms in patients with obsessive-compulsive disorder who have failed to respond sufficiently to SRIs. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - January 1, 2016 Category: Neurology Tags: Original Articles Source Type: research

Improvements in body composition, anthropometric measurements and lipid profile following discontinuation of clozapine.
CONCLUSIONS: Clozapine may cause severe, but reversible metabolic abnormalities, including obesity and hypertriglyceridaemia. Atypical antipsychotic-related lipid abnormalities may have a very rapid onset, occur in relatively young patients, with severe lipid derangements and have potential serious complications. This case confirms how important is to monitor metabolic parameters in patients taking antipsychotics. Discontinuation or switching to another antipsychotic medication may improve components of the metabolic syndrome. PMID: 26140393 [PubMed - in process] (Source: Nordic Journal of Psychiatry)
Source: Nordic Journal of Psychiatry - December 25, 2015 Category: Psychiatry Tags: Nord J Psychiatry Source Type: research

Supplement to Nov-Dec 2015 Issue: Abstracts of Poster Presentations: CNS Summit 2015
This study compared the next-day residual effects of acute and steady-state nighttime doses of flibanserin (100mg/day and 200mg/day) on simulated driving performance and cognition in healthy female subjects. Objective: To test for negative effects on measures of next-day simulated driving performance and cognitive testing Methods: Healthy, premenopausal females (18–-50 years of age) were randomized to flibanserin (100mg or 200mg), zopiclone (7.5mg), or matching placebos the evening prior to testing in a double-blind, placebo-controlled, Latin-square design, with four-way, four-period crossover (n=83). Zopiclone was s...
Source: Innovations in Clinical Neuroscience - December 2, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Current Issue Drug Development Genetics Supplements Trial Methodology CNS Summit poster presentation abstracts Source Type: research